Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacodynamics of Increasing Subcutaneous Doses of SELA-070 in Healthy Adult Smokers
Sponsor: Selecta Biosciences, Inc.
Listed as NCT03148925, this PHASE1 trial focuses on Smoking Cessation and remains completed. Sponsored by Selecta Biosciences, Inc., it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Oct 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE1
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Selecta Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .